1492. Prevalence of chronic kidney disease among HIV-infected individuals in Japan: a multicenter study based on the 2012 KDIGO classification
Session: Poster Abstract Session: Global HIV
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDSA 2013.pdf (163.8 kB)
  • Background: Chronic kidney disease (CKD) is now epidemic among HIV-infected populations in both Western and Eastern countries, and associated closely with a poor prognosis in them. The 2012 KDIGO guidelines elaborated on how to identify CKD patients at high risk for adverse outcomes in the general population, by combining albuminuria with estimated glomerular filtration rate (eGFR).

    Methods: Ambulatory 1947 HIV-infected patients (1829 men, 118 women, mean age: 44.9 11.5 years) who regularly visited either of the 5 tertiary hospitals in Japan were categorized, based on the new KDIGO CKD classification. Urinary albumin to creatinine ratio (ACR) was classified into 3 grades: [A1] ≤ 30mg/g, [A2] 30 - 299mg/g, and [A3] ≥ 300mg/g. eGFR was classified into 6 grades: [G1] 90 ≤, [G2] 60 - 89, [G3a] 45 - 59, [G3b] 30 - 44, [G4] 15 - 29, and [G5] < 15 mL/min/1.73 m2. Prevalence of CKD at likely high risk was compared with that according to the conventional CKD staging.

    Results: The prevalence of CKD ≤ stage 2 and that of CKD ≥ stage 3 classified according to the CKD staging was 90.8% and 9.2%, respectively. The prevalence of CKD categories 0+1 (low and moderately increased risks) and that of CKD categories 2+3 (high and very high risks) was 95.2% and 4.8%, respectively. This indicated that the new classification provided a reduction of nearly 50% in the proportion of high-risk CKD (Figure).

    Conclusion: The KDIGO classification may facilitate targeting of high-risk CKD in HIV-infected individuals.

    Naoki Yanagisawa, MD1,2, Takashi Muramatsu, MD3, Tomohiko Koibuchi, MD, PhD4, Akihiro Inui, MD5, Yusuke Ainoda, MD, PhD6, Toshio Naito, MD5, Yasuyuki Yamamoto, MD, PhD3, Kosaku Nitta, MD, PhD2, Atsushi Ajisawa, MD, PhD1, Katsuyuki Fukutake, MD, PhD3, Aikichi Iwamoto, MD, PhD4 and Minoru Ando, MD, PhD2,7, (1)Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, (2)Department IV of Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan, (3)Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan, (4)Department of Infectious Diseases and Applied Immunology, Research Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, (5)Department of General Medicine, Juntendo University School of Medicine, Tokyo, Japan, (6)Department of Infectious Diseases, Tokyo Women's Medical University, Tokyo, Japan, (7)Department of Nephrology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

    Disclosures:

    N. Yanagisawa, None

    T. Muramatsu, None

    T. Koibuchi, None

    A. Inui, None

    Y. Ainoda, None

    T. Naito, None

    Y. Yamamoto, None

    K. Nitta, None

    A. Ajisawa, None

    K. Fukutake, None

    A. Iwamoto, None

    M. Ando, None

    See more of: Global HIV
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.